Vaxcyte, INC Form 4 insider transactions

Vaxcyte's Chief Operating Officer, Jim Wassil, reports multiple transactions involving the company's common stock and stock options.

Vaxcyte's Chief Operating Officer, Jim Wassil, reported a transfer of 74,000 common stock shares to a charitable remainder trust on December 31, 2024.

Grant Pickering, CEO of Vaxcyte, reports acquisition of shares through restricted stock units and disposition of shares to cover tax obligations.

Vaxcyte's President and CFO, Andrew Guggenhime, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte's Chief Operating Officer, Jim Wassil, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte's President and CFO, Andrew Guggenhime, exercised stock options and sold shares on January 21, 2025, under a pre-arranged 10b5-1 trading plan.

Vaxcyte director Teri Loxam sold a total of 7,250 shares of common stock on January 15, 2025, under a pre-arranged 10b5-1 trading plan.

Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., reports exercising stock options and selling shares under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte's Chief Operating Officer, Jim Wassil, executed stock sales and exercised stock options on January 2, 2025, according to a recent SEC filing.

Vaxcyte's President and CFO, Andrew Guggenhime, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Elvia Cowan, SVP of Finance at Vaxcyte, Inc., exercised stock options and sold shares on December 16, 2024.

Director Carlos V. Paya of Vaxcyte, Inc. reports the transfer of shares to a family trust and the grant of stock options.

Vaxcyte CEO Grant Pickering sold a total of 2,366 shares of common stock on December 9, 2024, through a pre-arranged 10b5-1 trading plan.

Vaxcyte's SVP, General Counsel & Corporate Secretary, Mikhail Eydelman, reported multiple transactions involving the company's stock, including a gift, option exercise, and sales under a pre-arranged trading plan.

Vaxcyte CEO Grant Pickering sold a total of 15,000 shares of common stock in multiple transactions on December 2, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte's Chief Operating Officer, Jim Wassil, exercised stock options and sold shares on December 2, 2024, under a pre-arranged 10b5-1 trading plan.

Vaxcyte's President and CFO, Andrew Guggenhime, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Vaxcyte CEO Grant Pickering reported a gift of 710 common shares and details of beneficial ownership including shares held in trust for his children.

Elvia Cowan, SVP of Finance at Vaxcyte, Inc., was granted a performance stock option to purchase 11,900 shares of common stock on November 7, 2024.

Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., was granted a performance stock option to purchase 26,125 shares of the company's common stock.

Jim Wassil, Chief Operating Officer of Vaxcyte, Inc., was granted performance-based stock options and restricted stock units on November 7, 2024, subject to service and performance vesting conditions.

Andrew Guggenhime, President and CFO of Vaxcyte, Inc., received performance-based stock options and restricted stock units on November 7, 2024, as part of a company-wide grant.

Vaxcyte's CEO, Grant Pickering, reported the sale of common stock through a 10b5-1 trading plan and the grant of performance-based stock options and restricted stock units.

Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Vaxcyte's CEO, Grant Pickering, executed multiple sales of common stock on November 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte's Chief Operating Officer, Jim Wassil, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan on November 1, 2024.

Jim Wassil, Chief Operating Officer of Vaxcyte, Inc., reports exercising stock options at prices of $5.35 and $20.93 on October 28, 2024.

Andrew Guggenhime, CFO of Vaxcyte, Inc., executed stock options and sold shares on October 25, 2024.

Andrew Guggenhime, President and CFO of Vaxcyte, Inc., exercised stock options and sold shares of common stock on October 18, 2024, under a pre-arranged Rule 10b5-1 trading plan.